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Abstract
The lung is composed of airways and lung parenchyma, and the extracellular matrix (ECM) contains the main
building blocks of both components. The ECM provides physical support and stability to the lung, and as such it
has in the past been regarded as an inert structure. More recent research has provided novel insights revealing
that the ECM is also a bioactive environment that orchestrates the cellular responses in its environs. Changes in
the ECM in the airway or parenchymal tissues are now recognized in the pathological profiles of many respiratory
diseases, including asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF).
Only recently have we begun to investigate whether these ECM changes result from the disease process, or whether
they constitute a driving factor that orchestrates the pathological outcomes. This review summarizes our current
knowledge of the alterations in the ECM in asthma, COPD, and IPF, and the contributions of these alterations to the
pathologies. Emerging data suggest that alterations in the composition, folding or rigidity of ECM proteins may
alter the functional responses of cells within their environs, and in so doing change the pathological outcomes.
These characteristics highlight potential avenues for targeting lung pathologies in the future. This may ultimately
contribute to a better understanding of chronic lung diseases, and novel approaches for finding therapeutic
solutions.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
The extracellular matrix (ECM) provides structural
support and stability to the lung, and as such it has
previously been regarded as a non-stimulatory tis-
sue. Recent research has provided novel insights
indicating that the ECM is also a bioactive
milieu that sets the scene for cellular responses in
its environs.
In this review, we summarize the pathological alter-
ations and the consequent functional changes that
occur in three major lung diseases: asthma, chronic
obstructive pulmonary disease (COPD), and idiopathic
pulmonary fibrosis (IPF). In the near future, targeting
the ECM might be an alternative for the treatment of
chronic lung diseases.
Several chronic inflammatory diseases of the lungs
develop with an altered composition of the ECM.
Differing initial insults, or endogenous responses in
different regions of the lungs, result in distinct compo-
sitions in the remodelled ECM in each disease, causing
diverse functional outcomes. Several studies have
addressed the composition of the ECM in chronic lung
diseases such as asthma, COPD, and IPF, by studying
biopsy samples, resected tissues or autopsy samples
taken from the lungs at one time point (Figure 1). These
cross-sectional studies have presented sometimes con-
tradictory results, as different methods of analysis and
quantification were used, in diseases in different stages
or in different anatomical locations. Nevertheless, they
provide a basis for understanding ECM composition in
human chronic pulmonary diseases.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
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Figure 1. Histochemical staining of lung tissue sections. (1, 2) Large cartilaginous airway, small airway and surrounding alveolar parenchyma
of a normal lung. Note the normal thickness of the mucosa, and the absence of inflammation. The alveoli have a normal size and architecture,
and no fibrosis. (3, 4) Large airway and lung parenchyma of a patient with asthma. There is a thickened airway due to inflammation, and
some matrix deposition, mainly at the submucosal level. The parenchyma shows an area of hyperinflation, but no fibrosis. (5, 6) Small
airway and lung parenchyma in a patient with COPD. There is parenchymal destruction (emphysema) and some peribronchiolar fibrosis. (7,
8) Small airways and the lung parenchyma of a patient with IPF. There is architectural disorganization of the parenchyma around a dense
fibrotic area, with cystic areas involving part of the parenchyma. The detail shows fibroblastic foci with areas of collagen deposition along
alveolar walls. Verhoeff–Masson staining. Collagens are in blue, muscle is in red, and EFs are in black.
The ECM in diseases of the lungs
Asthma
Thickening of the airway basement membrane (BM)
was the initial structural alteration described in asthma
[1]. It consists of thickening of the subepithelial lamina
reticularis that lies beneath the true basal lamina of the
bronchial epithelium, involving accumulation of colla-
gens I, III and IV and fibronectin [2]. In non-asthmatics,
the thickness of the lamina reticularis is approximately
5–6 μm, whereas it is consistently thickened in biopsies
of asthmatics, with mean values of∼9 μm [3]. BM thick-
ening develops early in the disease course, and persists
after remission [4]. However, in both adults and children,
there is a lack of association between BM thickness and
disease duration or severity [5]. The ultrastructure of the
collagen fibres in the thickened BM in asthma consists of
an accumulation of (thinner) reticulin fibres rather than
the (thicker) interstitial fibres, suggesting that the accu-
mulation of collagen in asthma is different from that in
interstitial lung diseases [6].
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 397–409
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
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An altered composition of major ECM compo-
nents has been described in all lung compartments
in asthma [central airways, airway smooth muscle
(ASM), distal parenchyma, and vessels], and the
results vary according to asthma severity, control of
disease, age, and use of corticosteroids [7]. The main
effector in asthma is the ASM, which secretes ECM
components and, in turn, is functionally responsive to
the ECM’s composition, with the ECM deposited by
asthma-derived ASM enhancing growth and cytokine
output as compared with that in non-asthmatics [8,9].
There is no relative increase in the ECM in relation to
the increased ASM mass in cases of fatal asthma [10],
but there are altered contents of fibronectin, elastin
fibres (EFs), matrix metalloproteinase (MMP)-9, and
MMP-12 [11]. Patients with moderate asthma have
more proteoglycans (PGs) within the ASM than those
with severe asthma, suggesting that PG deposition
may be protective [12]. In mild asthmatics, despite
no differences in ECM gene expression between
asthmatics and controls, there are structure–function
relationships between the fractional composition of
the ECM within the ASM layer and indices of bron-
choconstriction and bronchodilation in asthmatics
[13]. In fatal asthma, more pronounced changes in
the small airways are observed in relation to PG, gly-
coprotein and collagen contents than in the central
airways [14,15]. These changes, which are associated
with rupture of alveolar attachments and a decreased
elastin content, imply important involvement of the
small airways in asthma pathophysiology, but further
research is needed to understand the role of these ECM
changes [16].
Lack of control and asthma severity are associated
with changes in ECM composition, in both the central
and the distal airway compartments. In severe asthma,
there is increased deposition of collagen I and III and
an increased ASM mass in bronchial biopsies [17,18].
In uncontrolled asthma, important differences have been
reported in PG composition in both central airways and
the alveolar parenchyma, such as increased percentage
areas of collagen, versican and decorin as comparedwith
patients with controlled asthma [19].
Access to airway tissue with functional correlates
in asthma is restricted to endobronchial biopsies in
the research setting, making structure–function stud-
ies related to the ECM difficult to conduct. The use of
bronchial thermoplasty to treat severe asthma reduces
ASMmass in biopsies 3months after the procedure [20],
but there are still no data regarding which changes in the
ECM occur in the treated mucosa. Such information is
important for the future development of targeted inter-
ventions that do not require this invasive procedure.
Chronic obstructive pulmonary disease
The instillation of elastolytic enzymes, with the sub-
sequent development of emphysema, in the lungs of
animals led to the recognition that the destruction of
EFs was central in the pathogenesis of COPD [21]. The
ultrastructure of EFs is abnormal in COPD patients,
with finely disrupted fibres, vacuoles and electron-dense
deposits, and signs of abnormal elastogenesis [22], with
several studies showing reductions in EFs in the lung
parenchyma of individuals with COPD as compared
with ‘healthy smokers’, associated with loss of lung
function [23,24]. Indeed, in severe COPD, increased
gene expression of elastin is not accompanied by an
increase in EF content per unit lung volume [25]. A large
study of lung gene expression showed that several genes
related to elastogenesis were upregulated in the lungs of
COPD patients, including that for fibulin-5, a glycopro-
tein involved in EF assembly [26]. The main cell type
responsible for ECM production in COPD is thought to
be the fibroblast/myofibroblast, but the ASM and epithe-
lial cells also contribute to the ECM pool detected in
these gene expression studies.
Interestingly, elastic reduction is not limited to the
lung parenchyma, but is also observed in the small and
large airways of COPD patients [24]. This suggests that
the loss of EFs in COPD is involved in airway obstruc-
tion not only by causing loss of airway–parenchyma
coupling and hence airway collapse upon forced expi-
ration, with subsequent air trapping, but also by altering
the structural support of the airways.
Reports on the collagen content in COPD lungs
are conflicting, with increased total collagen having
been found in lungs of patients with emphysema [27].
However, expression levels of genes related to colla-
gen production were decreased in the lungs of COPD
patients [28]. Annoni et al reported that COPD patients
have less collagen I in the airways, potentially favour-
ing airway collapsibility [24]. Similarly, Annoni et al
[24] observed a decreased versican content in the lung
parenchyma in moderate COPD, whereas Merrilees
et al described an increased content in the same lung
area, although they used different quantification meth-
ods [29]. Van Straaten et al described a decrease in the
contents of the PGs decorin and biglycan in patients
with severe emphysema [30]. The contents of other
ECM components, such as tenascin and fibronectin, are
increased in COPD patients [24].
At the microscopic level, advances in imaging tech-
nology are enabling a greater understanding of the
three-dimensional assembly of the ECM in COPD. Sec-
ond harmonic generation (SHG), which has been used
in the physical sciences for decades, has recently been
validated for studying collagen I structural changes
in COPD [31,32] (Figure 2; supplementary material,
Movies S1–S6). In addition, the intrinsic fluorophore
properties of elastin have been harnessed through the use
of two-photon and multiphoton fluorescence techniques
to reveal complex collagen and elastin networks not pre-
viously identified by conventional microscopy [31,32].
Characterizing the functional implications of the alter-
ations in ECM proteins in COPD lungs will provide
a greater understanding of the mechanisms driving the
perpetuation of lung destruction in the parenchymal
regions, while fibrotic deposits line the small airways.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 397–409
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
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Figure 2. Representative SHG images of regions from the small airways mucosa or lung parenchyma from healthy donors or patients with
asthma, COPD, or IPF. Yellow: backward immature/disorganized collagen. Cyan: mature/organized collagen.
Idiopathic pulmonary fibrosis
Massive deposition of heterogeneously distributed ECM
components in the alveolar parenchyma is a major
characteristic of IPF. Structural alterations are present
mainly in the alveolar regions, but also affect the ter-
minal airways. These pathological alterations lead to
a restrictive pattern and lower volumes on spirometry,
with reduced gas transfer [33].
Fibroblastic foci, which constitute a singular charac-
teristic of IPF, among other interstitial lung diseases, are
accumulations of myofibroblasts, adjacent to areas of
apoptotic or hyperplastic alveolar epithelial cells. Acti-
vated fibroblasts and myofibroblasts are believed to be
the major producers of the ECM.
Immunohistochemical studies in the 1980s described
depositions of collagens (mainly types I and III) and
fibronectin along alveolar septa in chronic fibrotic
diseases. Collagen III seems to predominate in early
IPF, whereas collagen I dominates in late-stage disease.
(Figure 2; supplementary material, Movies S3-S6).
Authors initially reported that fibrosis occurred in foci
near the air–tissue interface, localized outside rem-
nants of a disrupted basal lamina and therefore within
airspaces, providing support for the current concept
of local, recurrent alveolar epithelial injury being cen-
tral in the pathogenesis of IPF [34,35]. Roberts et al
reported that fibroblast foci stained heavily for versican,
to a lesser degree for hyaluronan, and very little for
decorin and biglycan. The versican-rich areas contained
little mature collagen, but the myofibroblasts in these
areas stained for type I procollagen, suggesting early
collagen synthesis [36]. The tenascin-C content was
also increased in the fibroblast foci [37]. These data
reinforce the idea that, in fibroblast foci, active matrix
remodelling occurs and that early versican deposition
may drive the process.
The content of EFs was also increased in fibrotic
areas in IPF patients, and correlated with the degree
of collagen deposition in biopsies. In addition, patients
with high EF scores had worse outcomes than those
with low scores, and EF score was an independent
predictor of poor prognosis. EFs are needed to provide
physiological elastic recoil within the lungs, but excess
amounts of EFs affect the ‘hardness’ or ‘stiffness’ of the
lungs, and increase the work of breathing in the early
inspiratory phase, owing to enhanced elastic recoil [38].
It remains to be established whether the altered com-
position of the ECM is particular to IPF or occurs in
other chronic fibrotic interstitial lung diseases. Estany
et al studied lung gene expression of glycoproteins such
as tenascin, fibronectin, and versican, and found no dif-
ferences between IPF and chronic hypersensitivity pneu-
monitis [37].
Parker et al recently introduced the interesting
concept that the remodelled ECM activates a posi-
tive pro-fibrotic feedback loop [39]. They cultivated
control and IPF-derived fibroblasts in de-cellularized
matrix from controls and IPF patients. Surprisingly,
IPF-derived matrix had a greater impact on gene
expression than the origin of the cell, with prominent
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 397–409
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
The impact of extracellular matrix in lung disease 401
alterations in translational control being seen. Genes
coding for ECM proteins in IPF were also targets
of miR-29, which was downregulated in IPF-derived
fibroblasts, suggesting a higher level of ECM pro-
tein expression. This study opens avenues for the
development of new therapeutic strategies.
Responses of the ECM to corticosteroids
Corticosteroids constitute a mainline therapeutic strat-
egy for managing inflammatory diseases in the lungs.
However, the effectiveness of these treatments in pre-
venting or reversing the ECM remodelling described
above in asthma, COPD and IPF is controversial.
Although collagens do not respond to corticosteroid
treatment in severe asthma, a 2-week course of budes-
onide increased the content of the PGs versican and
biglycan, showing the selective action of corticosteroids
on airway structure in asthma [40]. Similarly, COPD
patients receiving 30months of inhaled fluticasone had
increases in airway collagen III and versican contents as
compared with patients receiving placebo [41]. Treat-
ment with steroids may hence contribute to stabilization
of the airway structure in COPD.
In vitro data on the influence of corticosteroids on
ECM production are also conflicting. Corticosteroids
induced ECM protein production from ASM cells
[42–45], and the combination of budesonide and fluti-
casone induced collagen I and fibronectin production
[46]. Interestingly, Goulet et al reported that, in primary
human lung fibroblasts, glucocorticoids increased total
ECM and collagen deposition in the presence of serum,
but not in the absence of serum [47]. In contrast, glu-
cocorticoids reduced the production of ECM proteins
from bovine tracheal ASM cells [48], fibroblasts [49],
and sputum cells [50].
The efficiency of current therapeutic approaches for
addressing ECM changes in lung diseases is an underex-
plored area. Finding mechanisms for targeting the detri-
mental ECM changes in the lung has the potential to
provide a wealth of information leading to future break-
throughs in the management of lung pathologies.
Cellular sources of ECM proteins
Fibroblasts and myofibroblasts are the main producers
of ECM components in the lung, but airway epithelial
cells and ASM cells are also important sources. Fibrob-
lasts are key players in regulating the homeostasis of
ECMproteins by coordinately secretingMMPs and their
inhibitors and integrating signals from the ECM, a topic
that has been reviewed elsewhere [51]. Integrins are key
molecules that mediate cell–cell and cell–ECM interac-
tions, which also influence the ECM balance in the cel-
lular microenvironment. The role of integrins in airway
remodelling and their potential as therapeutic targets has
recently been reviewed [52]. No distinguishing differ-
ences in the cellular sources of ECM between asthma,
COPD and IPF have been identified to date. We have
a limited understanding of the mechanisms governing
the switch from healthy to diseased stroma. When tis-
sues are damaged and normal wound-healing responses
become dysregulated, fibrosis occurs. Most chronic
fibrotic disorders have in common a persistent agent
(often unknown) that sustains the production of growth
factors, proteolytic enzymes, angiogenic factors, and
fibrogenic cytokines, which stimulate the deposition of
ECM that progressively remodels tissues [53] (Figure 3).
In response to injury, fibroblasts migrate towards the
site of injury, and ultimately differentiate into myofi-
broblasts, which specialize in ECM production. The ori-
gin and differentiation potential of fibroblasts are very
dynamic, and may result in unique patterns of the ECM
in different lung disorders [54]. Lung-resident fibrob-
lasts contribute greatly to the ECM in health, and are
able to differentiate into muscle-like contractile myofi-
broblasts, adopt a migratory phenotype, or proliferate in
response to injury cues [55–57]. Myofibroblasts deposit
collagen types I and III during fibrotic events, but also
collagen type IV, various PGs, and glycoproteins such as
laminins and fibronectin.
Severalmesenchymal progenitor cells in the lung have
been discovered to be involved in fibrotic events, includ-
ing fibrocytes, mesenchymal stromal cells (MSCs), and
pericytes. One particular distinct perivascular cell type,
which expresses ADAM12 and platelet-derived growth
factor receptor-α, has a specific profibrotic fate. Inter-
estingly, the cellular progeny of ADAM12-positive cells
is restricted to profibrotic cells, and not other mes-
enchymal derivatives such as adipocytes, suggesting that
these cells are distinct from MSCs or pericytes [58].
The MSCs in lung are located perivascularly, main-
tain the capacity to differentiate into bone, adipose
and chondrocyte tissue in vitro, and, importantly, are
organ-resident [59], but their role is not clear [60].
Fibrocytes are progenitor cells originating from bone
marrow, and show both haematopoietic cell surface
markers (CD45 and CD34) and mesenchymal mark-
ers (prolyl-4-hydroxylase and α-smooth muscle actin),
and typically also the chemokine receptor CXCR4 [61].
Importantly, they home to locations with ongoing tis-
sue remodelling in IPF through the CXCL12–CXCR4
chemokine axis and differentiate into fibroblasts [62].
CXCR4 is expressed on 90% of all fibrocytes, making
it a potential target in IPF [63]. Fibrocytes have also
been observed in asthma and bronchiolitis obliterans,
suggesting that these cells are important in the perpet-
uation of lung disease [62,64,65]. The interaction of
fibrocytes and the feedback that they receive from the
lung ECM niche in different diseases in which fibrosis
is involved is of great importance. Importantly, epithelial
cells may contribute to the fibroblast pool in lung disease
through epithelial-to-mesenchymal transition (EMT), a
process whereby epithelial cells gradually lose epithelial
markers (loss of E-cadherin) and acquire a mesenchy-
mal (fibroblast-like) cell phenotype (gain of N-cadherin)
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 397–409
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Figure 3. Model of events contributing to fibrosis in lung disease. (A) The common view that persistent inflammatory responses contribute to
fibrosis. (B) In response to injury and fibrotic events, fibroblasts migrate towards the site of injury, proliferate, and ultimately differentiate
into myofibroblasts. These cells specialize in ECM production. (C) Several mesenchymal progenitor cells in the lung may be involved in
fibrotic events and contribute to the fibroblast pool in lung fibrosis, including fibrocytes, MSCs, pericytes, and potentially other progenitors.
Epithelial cells may contribute to the fibroblast pool through EMT. (D) Migration is influenced in a complex way by tissue stiffness.
[66]. Several different strategies targeting fibrosis are
emerging, and new tools that mimic the in vivo situation
to manipulate disease mechanisms are being developed
[67–69]. These approaches focusing on this previously
underexplored source of ECM-producing cells deserve
greater attention.
The differences in occurrence, levels, location pat-
terns and activity of the described cells, i.e. fibroblasts,
myofibroblasts, MSCs, pericytes, and fibrocytes, mirror
the state of the disease of the patient, and are not spe-
cific for a distinct lung disease such as COPD/asthma
or IPF. However, these types of more complex compar-
ison study are clearly warranted in the future, whereby
patients with different lung diseases, in the same state
of disease, and from whom biopsy sampling is possible,
are compared to allow fingerprinting of distinct disease
mechanisms and phenotypes, and also new biomarkers.
Shaping of the ECM
The many components of the ECM dictate the need
for a highly regulated assembly process to bring all
of the pieces together in a structured, organ-specific
manner (reviewed recently in [70]). Although our
understanding of the roles that many of the components
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 397–409
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play within the structure is limited, it is clear that the
assembly of the ECM provides unique tissue-specific
microenvironments.
Importantly, the ECM is a highly dynamic environ-
ment, with some molecules changing rapidly and other
components maintaining a steady state. Parts of the
ECM are being constantly remodelled and subjected
to post-transcriptional changes [71]. Collagen turnover
rates in the lung have been estimated to be up to
10–15% per day [72]. Interestingly, collagen synthesis
rates decrease with age, and the proportion of newly syn-
thesized collagen degraded in a mouse increased from
27% in a young animal (1month) to 82% in an old ani-
mal (15months) [73]. PG turnover has been reported
to occur a slower rate than collagen turnover in other
organs, ranging from 3 to 70 days [74,75]. In contrast,
EF proteins are remarkably long-lived, with an estimated
mean stability duration of 74 years in humans [76], and
do not show a correlation with age [77].
The dynamic nature of the ECM is directed by the
synthesis rates of the individual components and also by
the surfeit of proteases that are released by both resi-
dent mesenchymal and inflammatory cells in the lung.
MMPs, in particular, have received considerable atten-
tion in the endeavour to elucidate mechanisms driv-
ing ECM remodelling in the respiratory system [78].
Although it is recognized that this is a level of control
of the ECM state that can be disrupted during disease,
this will not be reviewed extensively here. Interestingly,
enhanced ECM degradation has recently been reported
in COPD exacerbations, suggesting that there may be a
link between the rate of ECM turnover during disease
exacerbations and disease progression [79]. This is an
under-recognized element of lung pathology that should
be a focus for research in the future.
ECM stiffness
The stiffness of the ECM in the lung is directly related
to the biomechanical properties of the tissue. The fib-
rillary ECM proteins (e.g. collagen and fibronectin)
are responsible for the tensile strength, whereas the
elastic recoil is provided by the elastin molecules
[21,80]. Changes in the levels and ratios of these
proteins, as seen in asthma, COPD, and IPF, impact
on the relative contributions of the proteins to ECM
stiffness [81]. Normal human lung parenchyma has
a stiffness of 0.44–0.75 kPa (depending on whether
the alveolar wall, airway wall or airway epithelium is
measured), whereas IPF lung tissue has a stiffness of
50 kPa [82], and emphysematous tissue has a reduced
stiffness [83]. The enhanced collagen deposition in IPF
is associated with the enhanced stiffness in this ECM
[82]. Similarly, the increased fractional area of tenascin
and fibronectin in the COPD ECM, which indicates
relative elastin destruction, may be linked to the reduced
stiffness [84].
The ECM also acts as a reservoir for growth fac-
tor deposition, with transforming growth factor (TGF)-β
being well recognized as being secreted in an inac-
tive form that is bound in the ECM by the latent
TGF-β-binding protein [85]. ECMbiomechanical forces
are important for activation of TGF-β, and stiffer matri-
ces promote enhanced activation of TGF-β, suggesting
that the stiffer ECM in IPF generates a feedback loop
that exacerbates pro-fibrotic signalling in this microen-
vironment [86].
The ECM structural assembly is regulated by enzy-
matic and non-enzymatic cross-linking, which also
influence the stiffness of the ECM by altering the
physical characteristics of the ECM and strengthening
protein–protein interactions within the structure. These
alterations can change the resistance to degradation by
proteolysis, enhance cell–matrix interactions, and lead
to the emergence of neoepitopes, as reviewed in [87].
As decorin cross-links collagen fibrils, the decreases
in decorin and biglycan contents in smoking-related
emphysema impact on collagen cross-linking [30,88].
Lysyl oxidases and transglutaminases are the enzyme
families responsible for collagen cross-linking in the
ECM. Selective reduction of lysyl oxidase-like 2 levels
was recently investigated as a therapeutic approach for
IPF [89] (ClinicalTrials.gov NCT01769196). Although
a lack of efficacy led to the early termination of this trial,
ECM stiffness is an under-recognized area that deserves
greater attention as a potential therapeutic target in
lung diseases.
Cellular behaviours that are directed by the ECM
The ECM is a bioactive entity that has the capacity to
regulate many cellular behaviours that impact on lung
pathologies (Figure 4).
Migration
Cell migration is dependent on complex tissue
environments and their interactions with cellular biome-
chanical/chemical properties. Cells migrate in different
modes, but the common underlying process involves
polarization of the actomyosin-driven shape change of
the cell body [90]. Of great importance, migration is
influenced in a complex way by the confinement of cells
in the tissue, adhesion ligand density, such as integrin
binding to collagens, laminins, and fibronectins, and
stiffness and topology of the matrix [91,92]. The ECM
is therefore highly involved in cell migration, and bigly-
can and decorin induce morphological and cytoskeletal
changes in fibroblasts, resulting in an increase in cell
migration. Several intracellular signalling molecules
are upregulated in response to decorin and biglycan,
including the focal adhesion proteins paxillin and zyxin,
and some of the small Rho GTPases such as RhoA,
Rac1, and Cdc42 [93].
Proof of concept in disease
The mobility of fibroblasts in lung disease is commonly
affected and influenced by an altered ECM. Elongated
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 397–409
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
404 JK Burgess et al
Figure 4. A graphical representation of the complex cellular interactions with the ECM in the lung: potential impact on differentiation,
migration, adhesion, proliferation, tissue stabilization, homeostasis, and fibrosis. Cellular interactions with the ECM provide a positive
feedback loop to direct activities of the cells, alter tissue homeostasis, and drive fibrosis progression.
fibroblasts in the broncheoalveolar lavage fluid of mild
asthmatics migrated twice as far as fibroblasts originat-
ing from bronchial biopsies from the same patients, and
these fibroblasts also had increased production of bigly-
can, versican, and decorin, along with induced expres-
sion of RhoA and Rac1. These fibroblasts were not
found in healthy controls [57]. Interestingly, similar
results have been found in systemic sclerosis [94].
Proliferation
The ECM is a strong determinant of cell proliferation.
Many ECM proteins, including collagen I, fibronectin,
laminin, biglycan, decorin, and versican, have been
reported to influence cell proliferation. Collagen I and
fibronectin promote ASM cell proliferation, whereas
laminin chains induce apoptosis [95,96]. The core
protein of biglycan and decorin binds cytokines such as
TGF-α [97], but the fine structures of the side chains of
PGs also have a great impact, owing to their potential to
interact with cytokines and growth factors. For example,
glycosaminoglycan side chains rich in L-iduronate have
been found to inhibit the proliferation of fibroblasts [98]
by potentially binding growth factors [99]. Similarly,
heparan sulphate PG (HSPG) is known for its antipro-
liferative effect; however, treating fibroblasts with
HSPG together with platelet-derived growth factor-BB
enhances mitogenicity. The ECM derived from cells
isolated from patients with asthma induced a greater
proliferative capacity than that from cells from people
without asthma [9], and these matrices have been shown
to have defined differences in ECM proteins that have
previously been reported to be proproliferative [9,42].
These complex effects indicate that the ECM itself
may regulate cell proliferation by affecting the expres-
sion of receptors for cytokines and growth factors,
which may initiate both stimulatory and inhibitory
signals [100].
Proof of concept in disease
There are great differences in distal versus central lung
airways in several different lung disorders, in terms of
both the composition of the ECM and the phenotypic
differences in mesenchymal cells, including prolifer-
ation and ECM production [19,56]. Centrally derived
fibroblasts are larger and have more projections than
distal fibroblasts [101]. In addition, distal fibroblasts
have a higher proliferative potential than central fibrob-
lasts from healthy subjects [56] or asthma patients
[101], but not than those from COPD patients, which,
intriguingly, had a lower proliferation potential than
those from control subjects. In contrast, ASM cells
from asthma patients proliferate at a higher rate than
those from healthy subjects [102,103]. In pulmonary
fibrosis patients, fibroblast populations that are high
producers of hyaluronan and decorin and have lower
proliferative potential may play a crucial role in the
pathogenesis of fibrosis [104]. Also after lung trans-
plantation, the production of perlecan and decorin has
been noted to negatively correlate with fibroblast pro-
liferation, which may represent early signs of ongoing
remodelling and potential markers for Bronchiolitis
Obliterans Syndrome (BOS) [55].
Cellular responses to the stiffness of the
microenvironment
Alterations in collagen fibre structure and stiffness are
of great importance for tissue structure and elastic-
ity, but also for fibroblast responses. Indeed, stiffen-
ing of the ECM during remodelling and the develop-
ment of fibrosis affects cell adhesion and migration, so
that cells migrate towards a stiffer ECM [105]. Fibrob-
lasts increase their spread area, increase actin stress
fibre formation and form larger focal adhesion com-
plexes as the culture substrate stiffness increases. Cell
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 397–409
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Figure 5. The remodelled ECM in the lungs is produced by multiple cell types, and in turn modulates the behaviour of the cells to impact
on the perpetuation of disease pathology. Blue arrows indicate a positive/promoting effect, and red arrows indicate a negative/inhibitory
effect. COLI, collagen I; COLIII, collagen III; COLIV, collagen IV; FN, Fibronectin.
proliferation is also increased with increased substrate
stiffness. These changes require localization of the
nuclear transcriptional regulator Yes-associated protein
(YAP) in the cell nucleus [106], and this event is tightly
coupled to larger traction force generation. In culture,
YAP accumulates in the nuclei of fibroblasts grown
on pathologically stiff matrices but not on physiolog-
ically compliant matrices, and may therefore be heav-
ily involved in amplifying and sustaining pathological
fibrosis [107].
Proof of concept in disease
Pathological fibrosis is both a cause and a consequence
of fibroblast activation. Interestingly, not only the ECM
but also cells themselves become stiffer in lung fibrotic
diseases. In scleroderma, atomic force microscopy
showed that fibroblasts were stiffer and had lower elas-
ticity than fibroblasts from healthy controls [108]. In
bleomycin-induced lung fibrosis, locally induced tissue
stiffness was accompanied by a change in fibroblast
phenotype from quiescence to progressively increasing
proliferation and matrix production. The increased
matrix stiffness also strongly suppressed fibroblast
production of cyclooxygenase-2 and prostaglandin E2
(PGE2), an autocrine inhibitory mechanism oppos-
ing fibrogenesis [109]. Differences in proliferation
and contraction, along with responsiveness to PGE2,
have been demonstrated between fibroblasts from IPF
patients and those from healthy controls, when fibrob-
lasts were grown on stiff matrices. Promisingly, these
differences were ablated when fibroblasts were grown
on soft matrices, even though IPF fibroblasts remained
relatively resistant to PGE2 [110]. De-cellularized lung
matrices from IPF patients are stiffer than matrices from
healthy controls [82], and induce fibroblasts to patho-
logically remodel the ECM [39]. Therefore, the stiffer
matrix has profound effects on cellular behaviour in
disease, providing a mechanism to enhance myofibrob-
last differentiation, ECM synthesis, and cross-linking,
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 397–409
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and thereby driving fibrosis progression. These data
give new hope for targeting mechanical cues and
pathways triggered by the ECM stiffness when cells are
unresponsive to anti-fibrotic agents.
Little is known about disease-specific changes in cel-
lular behaviours that are driven by the ECM. This is
an area where further research may provide signifi-
cant clues about mechanisms that may be targeted in
disease-specific manners as we strive to develop per-
sonalized medicine approaches for the management of
patients with lung diseases.
Why is it important to understand
the contribution of the ECM in lung diseases?
The course of many chronic lung diseases is associated
with changes in the composition, content and structural
ordering of the ECM components. Such changes vary
greatly between the different pathologies, with massive
deposition being seen in diseases such as IPF. In con-
trast, destruction predominates in others, such as in the
lung tissue of COPD patients, but here there is fibrosis in
the airway wall. To date, there are few therapeutic reg-
imens aimed at specifically treating ECM remodelling.
Changes in the ECM, which are driven by multiple cell
types in the lung, affect lung function and cell biology,
but, more importantly, dysregulation of the ECM seems
to provide a positive feedback loop to drive fibrosis pro-
gression (Figure 5).
We therefore need to understand much more about the
mechanisms underlying these changes and the resultant
in vivo processes. The positive results of the pirfenidone
[111] and nintedanib [112] phase III trials, demonstrat-
ing that agents targeting the different pathways that
drive lung fibrosis can reduce the progression of IPF,
provide excellent examples of why this understanding
is important [113]. It is also essential to understand how
currently available therapies interfere with ECM ele-
ments, such as the substitution of ASM with ‘fibrotic’
tissue by bronchial thermoplasty [114], or the pro-
longed use of corticosteroids or combination therapy
in asthma or COPD. Recognizing and investigating the
under-recognized elements of ECM remodelling in lung
pathologies provides an exciting opportunity to obtain
the next, urgently needed breakthrough to advance
our ability to reduce the mortality resulting from lung
diseases.
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SUPPLEMENTARY MATERIAL ONLINE
Movie S1. 3-dimensional SHG signals in a section showing an airway in an asthma patient’s lung tissue.
Movie S2. 3-dimensional SHG signals in a section showing an airway in a COPD patient’s lung tissue.
Movie S3. 3-dimensional SHG signals in a section showing an airway in an IPF patient’s lung tissue.
Movie S4. 3-dimensional SHG signals in a section showing alveoli in an IPF patient’s lung tissue.
Movie S5. 3-dimensional SHG signals in a section showing an airway in non-diseased lung tissue.
Movie S6. 3-dimensional SHG signals in a section showing alveoli in non-diseased lung tissue.
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